Sign Out
Plaque psoriasis: Fraizeron is indicated for the treatment of moderate to severe plaque psoriasis in patients 6 years and older who are candidates for systemic therapy or phototherapy.
Psoriatic arthritis: Fraizeron, alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis in adult patients when the response to previous disease-modifying antirheumatic drug (DMARD) therapy has been inadequate.
Axial spondyloarthritis (axSpA) with or without radiographic damage: Ankylosing spondylitis (AS) / axSpA with radiographic damage: Fraizeron is indicated for the treatment of active ankylosing spondylitis in adults who have responded inadequately to conventional therapy.
Non-radiographic axial spondyloarthritis (nr-axSpA) / axSpA without radiographic damage: Fraizeron is indicated for the treatment of adult patients with active non-radiographic axial spondyloarthritis with objective signs of inflammation who have responded inadequately to conventional therapy.
Juvenile Idiopathic Arthritis (JIA): Enthesitis-Related Arthritis (ERA): Fraizeron is indicated for the treatment of active enthesitis-related arthritis in patients 6 years and older.
Juvenile Psoriatic Arthritis (JPsA): Fraizeron is indicated for the treatment of active juvenile psoriatic arthritis in patients 6 years and older.
Lanjutkan dengan Google